



Docket No.: 511582003500  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:

Mary FARIS, et al.

Application No.: 09/809,638

Art Unit: 1643

Filed: March 14, 2001

Examiner: A. Harris

For: 125P5C8: A TISSUE SPECIFIC PROTEIN  
HIGHLY EXPRESSED IN VARIOUS  
CANCERS

**DECLARATION BY INVENTORS**  
**UNDER 37 C.F.R. § 1.131**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

We, the undersigned, declare as follows:

1. We are co-inventors of claims 1, 14 and 23, currently pending in the above-referenced application. The claims relate to an isolated 125P5C8 protein comprising the sequence of SEQ ID NO: 2 or a polynucleotide sequence encoding the codons for SEQ ID NO: 2, which is exemplified by the nucleotide sequence of SEQ ID NO:1.

2. The Office rejected claims 1, 14 and 23 as allegedly being anticipated by WO 200270539 A2, which was filed March 5, 2002. This PCT application claims priority to U.S. Application No. 09/799,451, which was filed March 5, 2001, and is now U.S. Patent No. 6,783,989.

A copy of WO 200270539 was submitted in an Information Disclosure Statement provided in this application mailed on April 5, 2001. This document discloses sequence 1397 which is identical to SEQ ID NO: 2 of the present application.

3. We reduced the claimed invention to practice in the United States prior to the date U.S. Patent No. 6,783,989 was filed (March 5, 2001).

4. This reduction to practice is evidenced by a true and accurate copy of an email message sent to various members of the scientific staff by inventor Steve C. Mitchell on January 3, 2001. The email provides the nucleic acid and amino acid sequences of the material encompassed by the claims in the above-referenced patent application. A copy of this email is provided as Exhibit A.

5. The nucleotide sequence disclosed in Exhibit A consists of 2,103 nucleotides and 699 amino acids.



6. Exhibit B shows a comparison of the nucleotide sequence of SEQ ID NO:1 and the nucleotide sequence disclosed in Exhibit A. Every single nucleotide disclosed in SEQ ID NO:1 is present in the nucleotide sequence disclosed in Exhibit A. Accordingly, the email of Exhibit A clearly demonstrates the that nucleotide sequence of SEQ ID NO:1 was in our possession prior to the earliest priority date to which WO 200270539 (the cited art) is entitled to claim.

7. Exhibit C shows a comparison of the amino acid sequence of SEQ ID NO:2 and the amino acid sequence disclosed in Exhibit A. Every single amino acid residue disclosed in SEQ ID NO: 2 is present in the amino acid sequence disclosed in Exhibit A. Accordingly, the email of Exhibit A clearly demonstrates the that amino acid sequence of SEQ ID NO:2 was in our possession prior to the earliest priority date to which WO 200270539 (the cited art) is entitled to claim.

8. In view of the email provided as Exhibit A and the analysis of the sequences disclosed therein and shown in Exhibits B and C, we declare that the invention of the pending claims was reduced to practice in the United States prior to March 5, 2001, the earliest priority date available to the cited document.

We declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful, false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date Executed at

<u>01/26/06</u>	<u>Santa Monica, CA</u> (City/State)	 Aya JAKOBOVITS
		Daniel E.H. AFAR
		Steve Chappell MITCHELL
<u>1/27/06</u>	<u>Santa Monica, CA</u> (City/State)	 Pia M. CHALLITA-EID
<u>1-27-06</u>	<u>Santa Monica, CA</u> (City/State)	 Arthur B. RAITANO
		Mary FARIS

8. In view of the email provided as Exhibit A and the analysis of the sequences disclosed therein and shown in Exhibits B and C, we declare that the invention of the pending claims was reduced to practice in the United States prior to March 5, 2001, the earliest priority date available to the cited document.

We declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful, false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2/1/2006 FREMONT, CA  
(City/State) (City/State)

Aya JAKOBOVITS  
  
Daniel E.H. LEAR

---

(City/State)

---

**Steve Chappell MITCHELL**

---

(City/State)

---

**Ric M. CHALLITA EID**

---

(City/State)

---

Arthur B. BAITANO

---

(City/State)

---

Mary EARIS

**Popp, Shane**

**From:** Mitchell, Steve  
**Sent:** Wednesday, January 03, 2001 1:43 PM  
**To:** Scientists  
**Subject:** 125P5C8 reagents.

Colleagues,

The Company reagent for 125P5C8 (124P1B7/139P3A1) is pasted. It is a PCR based pCR2.1/TA clone(prostate) with three point differences from the Japanese (colon) reported hypothetical sequence. Two point are conserved for translation whereas the third point difference gives an amino acid change near the 3 prime end. This is verified with genomic sequencing.

>125P5C8(124P1B7/139P3A1) pCR2.1 subclone  
CGATGACCTCGCTGTGGAGAGAAATCCCTCTTGGAGTCGCTGCTGGGATGTGTTCTTGGCTCTCTACCATGACCTGGGACCGATG  
ATCTATTACTTCCCTTGCAAAACACTAGAACCTACTGGGCTTGAAGGTTTAGTATAGCATTCTCTCCAAATATCCCTAAACAATTACT  
CCTTCTGGAAATTGGTAAACAAGAAGTGGATGCTAACCCCTGCTGAGGATAATCACTATTGGCAGCATAGGCCTCCCTCCAGGCTCCA  
AATGCCAAACCTCGACTGATGGTCTTGGCCTTGGGTGCTTCCCTACTGATAGTCAAGCTGTGACTTGGTGGTGGGAAGTCAT  
TTGCAAAAGGTACCTCAGAATTGGGGATTCACTTCTAGGACAGATGTTCTTGTGCTACGCATATGGTATACTTCACTAAACCAAT  
CTGGAGTTATCAGATGTCACAAAGTGTGATGACTGACATTAAGTGGCCATAGGCCACACTTGATCGTATTGGCACAGATGGTGAUTGCAG  
TAAACCTGAAGAAAAGAAGACTGGTGAAGGTAGCCACGGGATGGCCTCTAGACCCAACTGGCTCTGGCAGGGGCTGCTTTGGT  
AGCCTTGTGTTCTCACCCACTGGGTTTGGAGAAGTCTCTCTGTTCCAGATGGGAGTGAAGTGGGATCCACATCCAGGGCC  
AGATCCTAACCCATTGGAGGTGCAAGTACTGCTGCTTGGCAAGTGGATGATGCTTOCATCTTGTGTTGGGTTCTGTGGTACTGG  
TTGATCTGGTGGGTTACAGGAACAGCTTCACTGCTGGGGGCTCTTACCTGCACACATGGGAGCTGCTGTGCTGGCTGTCT  
TCGCCATCTTACTGCATCATGTGGCCCCAACACTTGGACACCTTATTAACTCAGGGACAAACOCTGGGAAAACCATGACCATTG  
CCATGATATTTATCTCTAGAAATATTTCTGCTCTGGTCAAGACAGCTTAAAGTCTTGTCCCAGGGGTGCTACGCTAGAGAAAG  
ATCAGATGTGCTTTGGGACAATGATGTTAATTATCGGGCTGAATATGCTATTGGCTCAAGAAAACCTTGCTTGTCTTCAA  
ACAAAAAAACAGTCTAAAGTGTCTTCAAGAAAGAGTAAAAAATACATGAAACTTTCTGCTGGCTGCTTGTGTTGGGATTGTGG  
GATTAGGACTACGGCATAAACGCTATGAGAGAAAACCTGGGAAAGTGGCACCAACAAAGAGGTCTCTGCTGCCATCTGGCTTTC  
AGGTTGGATATGACAATGAGGGTGGCTAGTAAAGATCAGCTCACCTGCTCAATGAAACAGGTGCAAGATTCTATAACAATT  
TTGGAGAGTGTGCTTCAAGCCATATGGGAAACATGACTTAAACCATGTCAGCTGGCTAGGGAAAAGTTGGGTTCTATAACAGACTT  
GGTCCAAGCACAAGGTATCACACTGGGGATTATGGCTTGTCAAGATAACCCAAATTGTAATCTGAGCATCACCTTCTCCGTCA  
CCAGAGGGCGAGATCGCACAGCCATCACATTGACCGTTAACATTGGGCAAGCTGGGATTCTGCTGTGACACACTTGGAA  
ATATATCACTTCAGCACCTGGCTCCAGAGATTATCTACAGCTCACTGAACATGGCAATGTGAAGGATATGACAGCACTGATCATGA  
CAGATGGTGTGAATACATTATGTATCGAGGGCTGATCAGGTTATGCAAGAAATCTCCATGCTGAACGTGAGTGAATTGAGAAAT  
TCAGATGGCAAATTAGGATCCCTGATGACCCACTAATTATAGAGACAACAGAGAAGTGGTCAAGACCACAGAGAAGTTCTGA  
GAAAATTCTATTAATCCAGATTGGAT CCTACAAAGAAGGACACAATTATGAAAACAACCATCATTTATGAATACTCCAAAT  
ACTTTTATGAAAC  
>125P5C8(124P1B7/139P3A1) pCR2.1 subclone  
MTSLWREILLESLLGCVWSLYHDLGPMIYYFPQLOTLELTGLEGFSIAFLSPMFLTTPFWKLVNKKWMLTLRITIGSIAFQAPNAKLRLM  
/IALGVSSSLIVQAVTWWSGSHLORYLRIWGFILQIVLVLRLWYTSLNPIWSYQMSNKVILTLSAIATLDRIGTDGDCSKPEEKKTGEVA  
/GMASRPNWLLAGAAFGSLVFLTHWVGEVSLVSRWAVSGHPHPGPDPNPFGGAVLLCLASGLMLPSCLWFRGTGLWWVVTGTASAA  
/SLLYLHTWAAGSGCVFAITASMWPTLGHJINSGTNPGKTMITIAMIFYLLEIFFCAWCTAFKFPVGGVYARERSDVLGTMMIJIQLNML  
/GPKKNLDLQLTKNSKVLFRKSEKYMFLWLWLLVGVLGLGLRHKAYERKLKGKVAPTKVEVSAAIWPRFRGYDNEGWSLERSAHLL  
/IETGADFTILESASKPYMGNNDLTMWLGEKLGFYTDGPSTRYHTWGIMALSRYPIVKSEHHLLPSPEGEIAPAITLTVNISGKLVDVV  
/HFGNHEDOLDRKLQAJAVSKLLKSSSNQVFLGYITSAPGSRDYLOLTHEHGNVKDIDSTDHDRWCEYIMYRGLGYARISHAEISDSEI  
/MAKFRIPIPDDPTNYRDNQKVIDHREVSEKIHFNPRFGSYKEGHNYENNHHFHMTPKYFL

Steve Chappell Mitchell  
Associate Scientist  
uGenesys  
101 Colorado Avenue  
Santa Monica, CA 90404  
(310)820-8281 x281  
x (310)820-8489  
mailto: smitchell@urogenesys.com  
www.urogenesys.com

**Exhibit B**  
**A Comparison of SEQ ID NO.:1 and the Nucleotide Sequence of the Email**

atgacacctgc tggagaga aatccttgc gagtcgtgc tggtatgtgt ttcttggct SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
cg atgacacctgc tggagaga aatccttgc gagtcgtgc tggtatgtgt ttcttggct Email

ctctaccatg acctggacc gatgatctat tactttcatt tgcaaacact agaactca SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
ctctaccatg acctggacc gatgatctat tactttcatt tgcaaacact agaactca Email

gggcttgaag gtttagtat agcatttctt tctccaatat tcctaacaat tactccttc SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
gggcttgaag gtttagtat agcatttctt tctccaatat tcctaacaat tactccttc Email

tggaaattgg ttaacaagaa gtggatgcta accctgtga ggataatcac tattggcagc SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
tggaaattgg ttaacaagaa gtggatgcta accctgtga ggataatcac tattggcagc Email

atagcctcct tccaggctcc aaatgcaaa cttcgactga tggttcttgc gcttgggtg SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
atagcctcct tccaggctcc aaatgcaaa cttcgactga tggttcttgc gcttgggtg Email

tcttcctcac tgatagtgc agctgtgact tggtggtcgg gaagtcattt gcaaaggta SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
tcttcctcac tgatagtgc agctgtgact tggtggtcgg gaagtcattt gcaaaggta Email

ctcagaattt ggggattcat tttaggacag attgttcttgc ttgttctacg catatggat SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
ctcagaattt ggggattcat tttaggacag attgttcttgc ttgttctacg catatggat Email

acttcactaa acccaatctg gagttatcag atgtccaaca aagtgatact gacattaagt SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
acttcactaa acccaatctg gagttatcag atgtccaaca aagtgatact gacattaagt Email

gccatagcca cacttgcgtc tattggcaca gatggact gcagtaaac tgaagaaaag SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
gccatagcca cacttgcgtc tattggcaca gatggact gcagtaaac tgaagaaaag Email

aagactggtg aggtagccac gggatggcc tctagacca actggctgct ggcagggct SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
aagactggtg aggtagccac gggatggcc tctagacca actggctgct ggcagggct Email

gctttggta gccttgtt ctcacccac tgggttttg gagaagtctc tcttggttcc SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
gctttggta gccttgtt ctcacccac tgggttttg gagaagtctc tcttggttcc Email

**Exhibit B**  
**A Comparison of SEQ ID NO.:1 and the Nucleotide Sequence of the Email**

agatgggcag tgagtggca tccacatcca gggccagatc ctaaccatt tggaggtgca SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
agatgggcag tgagtggca tccacatcca gggccagatc ctaaccatt tggaggtgca Email

gtactgctgt gcttggcaag tggattgatg cttccatctt gtttgtggtt tcgtggtaact SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
gtactgctgt gcttggcaag tggattgatg cttccatctt gtttgtggtt tcgtggtaact Email

ggtttcatct ggtgggttac aggaacagct tcagctgcgg ggctccttta cctgcacaca SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
ggtttcatct ggtgggttac aggaacagct tcagctgcgg ggctccttta cctgcacaca Email

tggcagctg ctgtgtctgg ctgtgtcttc gccatcttta ctgcatccat gtggccccaa SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
tggcagctg ctgtgtctgg ctgtgtcttc gccatcttta ctgcatccat gtggccccaa Email

acacttggac accttattaa ctcaggaca aaccctggga aaaccatgac cattgccatg SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
acacttggac accttattaa ctcaggaca aaccctggga aaaccatgac cattgccatg Email

atatttatac ttctagaaat attttctgt gcctggtgca cagctttaa gtttgtccca SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
atatttatac ttctagaaat attttctgt gcctggtgca cagctttaa gtttgtccca Email

ggaggtgtct acgctagaga aagatcagat gtgctttgg ggacaatgat gttattttatc SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| |||||  
ggaggtgtct acgctagaga aagatcagat gtgctttgg ggacaatgat gttattttatc Email

ggctgaata tgctatttgg tcctaagaaa aaccttgcact tgcttcttca aacaaaaaac SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| |||||  
ggctgaata tgctatttgg tcctaagaaa aaccttgcact tgcttcttca aacaaaaaac Email

agttctaaag tgctttcag aaagagtcaa aaatacatga aacttttct gtggctgctt SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| |||||  
agttctaaag tgctttcag aaagagtcaa aaatacatga aacttttct gtggctgctt Email

gttggtgtgg gattgttggg attaggacta cggcataaaag cctatgagag aaaactgggc SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| |||||  
gttggtgtgg gattgttggg attaggacta cggcataaaag cctatgagag aaaactgggc

**Exhibit B**  
**A Comparison of SEQ ID NO.:1 and the Nucleotide Sequence of the Email**

aaagtggcac caaccaaaga ggctctgtc gccatctggc ctttcaggtt tggatatgac SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
aaagtggcac caaccaaaga ggctctgtc gccatctggc ctttcaggtt tggatatgac Email

aatgaagggt ggtcttagtct agaaagatca gctcacctgc tcaatgaaac aggtgcagat SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
aatgaagggt ggtcttagtct agaaagatca gctcacctgc tcaatgaaac aggtgcagat Email

ttcataacaa ttttggagag tgatgcttct aagccctata tggggAACAA tgacttaacc SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
ttcataacaa ttttggagag tgatgcttct aagccctata tggggAACAA tgacttaacc Email

atgtggctag gggaaaagtt gggTTTCTAT acagactttg gtccaaggcac aaggtatcac SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
atgtggctag gggaaaagtt gggTTTCTAT acagactttg gtccaaggcac aaggtatcac Email

acttggggga ttatggcttt gtcaagatac ccaattgtga aatctgagca tcaccttctt SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
acttggggga ttatggcttt gtcaagatac ccaattgtga aatctgagca tcaccttctt Email

ccgtcaccag agggcgagat cgccaccagcc atcacattga ccgttaacat ttcgggcaag SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
ccgtcaccag agggcgagat cgccaccagcc atcacattga ccgttaacat ttcgggcaag Email

ctggtgatt ttgtcgtgac acactttggg aaccacgaaat atgacctcgat caggaaactg SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
ctggtgatt ttgtcgtgac acactttggg aaccacgaaat atgacctcgat caggaaactg Email

caggctattg ctgtttcaaa actactgaaa agtagctcta atcaagtgtat atttctggga SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
caggctattg ctgtttcaaa actactgaaa agtagctcta atcaagtgtat atttctggga Email

tatatcactt cagcacctgg ctccagagat tatctacagc tcactgaaca tggcaatgtg SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
tatatcactt cagcacctgg ctccagagat tatctacagc tcactgaaca tggcaatgtg Email

aaggatatcg acagcactga tcatgacaga tggtgtgaat acattatgtat tcgagggctg SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
aaggatatcg acagcactga tcatgacaga tggtgtgaat acattatgtat tcgagggctg Email

atcaggttgg gttatgcaag aatctccat gctgaactga gtgattcaga aattcagatg SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
atcaggttgg gttatgcaag aatctccat gctgaactga gtgattcaga aattcagatg

**Exhibit B****A Comparison of SEQ ID NO.:1 and the Nucleotide Sequence of the Email**

gcaaaattta ggatccctga tgaccccact aattatagag acaaccagaa agtggtcata SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
gcaaaattta ggatccctga tgaccccact aattatagag acaaccagaa agtggtcata Email

gaccacagag aagtttctga gaaaattcat tttaatccca gatttggatc ctacaaagaa SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
gaccacagag aagtttctga gaaaattcat tttaatccca gatttggatc ctacaaagaa Email

ggacacaatt atgaaaacaa ccatcatttt catatgaata ctcccaaata ctttttatga SID#1  
||||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
ggacacaatt atgaaaacaa ccatcatttt catatgaata ctcccaaata ctttttatga Email

aac SID#1  
|||  
aac Email

**Exhibit C**  
**A Comparison of SEQ ID NO.:2 and the Nucleotide Sequence of the Email**

Met Thr Ser Leu Trp Arg Glu Ile Leu Leu Glu Ser Leu Leu Gly (SID #2)  
| | | | | | | | | | | | | | | |  
Met Thr Ser Leu Trp Arg Glu Ile Leu Leu Glu Ser Leu Leu Gly (Email)

Cys Val Ser Trp Ser Leu Tyr His Asp Leu Gly Pro Met Ile Tyr Tyr (SID #2)  
| | | | | | | | | | | | | | | |  
Cys Val Ser Trp Ser Leu Tyr His Asp Leu Gly Pro Met Ile Tyr Tyr (Email)

Phe Pro Leu Gln Thr Leu Glu Leu Thr Gly Leu Glu Gly Phe Ser Ile (SID #2)  
| | | | | | | | | | | | | | | |  
Phe Pro Leu Gln Thr Leu Glu Leu Thr Gly Leu Glu Gly Phe Ser Ile (Email)

Ala Phe Leu Ser Pro Ile Phe Leu Thr Ile Thr Pro Phe Trp Lys Leu (SID #2)  
| | | | | | | | | | | | | | | |  
Ala Phe Leu Ser Pro Ile Phe Leu Thr Ile Trp Pro Phe Trp Lys Leu (Email)

Val Asn Lys Lys Trp Met Leu Thr Leu Leu Arg Ile Ile Thr Ile Gly (SID #2)  
| | | | | | | | | | | | | | | |  
Val Asn Lys Lys Trp Met Leu Thr Leu Leu Arg Ile Ile Thr Ile Gly (Email)

Ser Ile Ala Ser Phe Gln Ala Pro Asn Ala Lys Leu Arg Leu Met Val (SID #2)  
| | | | | | | | | | | | | | | |  
Ser Ile Ala Ser Phe Gln Ala Pro Asn Ala Lys Leu Arg Leu Met Val (Email)

Leu Ala Leu Gly Val Ser Ser Ser Leu Ile Val Gln Ala Val Thr Trp (SID #2)  
| | | | | | | | | | | | | | | |  
Leu Ala Leu Gly Val Ser Ser Ser Leu Ile Val Gln Ala Val Thr Trp (Email)

Trp Ser Gly Ser His Leu Gln Arg Tyr Leu Arg Ile Trp Gly Phe Ile (SID #2)  
| | | | | | | | | | | | | | | |  
Trp Ser Gly Ser His Leu Gln Arg Tyr Leu Arg Ile Trp Gly Phe Ile (Email)

Leu Gly Gln Ile Val Leu Val Val Leu Arg Ile Trp Tyr Thr Ser Leu (SID #2)  
| | | | | | | | | | | | | | | |  
Leu Gly Gln Ile Val Leu Val Val Leu Arg Ile Trp Tyr Thr Ser Leu (Email)

Asn Pro Ile Trp Ser Tyr Gln Met Ser Asn Lys Val Ile Leu Thr Leu (SID #2)  
| | | | | | | | | | | | | | | |  
Asn Pro Ile Trp Ser Tyr Gln Met Ser Asn Lys Val Ile Leu Thr Leu (Email)

Ser Ala Ile Ala Thr Leu Asp Arg Ile Gly Thr Asp Gly Asp Cys Ser (SID #2)  
| | | | | | | | | | | | | | | |  
Ser Ala Ile Ala Thr Leu Asp Arg Ile Gly Thr Asp Gly Asp Cys Ser (Email)

### **Exhibit C**

## A Comparison of SEQ ID NO.:2 and the Nucleotide Sequence of the Email

Lys Pro Glu Glu Lys Lys Thr Gly Glu Val Ala Thr Gly Met Ala Ser (SID #2)  
| | | | | | | | | | | | | | | | | | | |  
Lys Pro Glu Glu Lys Lys Thr Gly Glu Val Ala Thr Gly Met Ala Ser (Email)

Arg Pro Asn Trp Leu Leu Ala Gly Ala Ala Phe Gly Ser Leu Val Phe (SID #2)  
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
Arg Pro Asn Trp Leu Leu Ala Gly Ala Ala Phe Gly Ser Leu Val Phe (Email)

Ala Val Leu Leu Cys Leu Ala Ser Gly Leu Met Leu Pro Ser Cys Leu (SID #2)  
| | | | | | | | | | | | | | | | | |  
Ala Val Leu Leu Cys Leu Ala Ser Glu Leu Met Leu Pro Ser Cys Leu (Email)

Trp Phe Arg Gly Thr Gly Leu Ile Trp Trp Val Thr Gly Thr Ala Ser (SID #2)  
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
Trp Phe Arg Gly Thr Gly Leu Ile Trp Trp Val Thr Gly Thr Ala Ser (Email)

Ala Ala Gly Leu Leu Tyr Leu His Thr Trp Ala Ala Ala Val Ser Gly (SID #2)  
| | | | | | | | | | | | | | | | | | | |  
Ala Ala Gly Leu Leu Tyr Leu His Thr Trp Ala Ala Ala Val Ser Gly (Email)

Phe Lys Phe Val Pro Gly Gly Val Tyr Ala Arg Glu Arg Ser Asp Val (SID #2)  
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
Phe Lys Phe Val Pro Gly Gly Val Tyr Ala Arg Glu Arg Ser Asp Val (Email)

**Exhibit C**

Leu Leu Gly Thr Met Met Leu Ile Ile Gly Leu Asn Met Leu Phe Gly (SID #2)  
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
Leu Leu Gly Thr Met Met Leu Ile Ile Gly Leu Asn Met Leu Phe Gly (Email)

Pro Lys Lys Asn Leu Asp Leu Leu Leu Gln Thr Lys Asn Ser Ser (SID #2)  
| | | | | | | | | | | | | | | | | | | |  
Pro Lys Lys Asn Leu Asp Leu Leu Leu Gln Thr Lys Asn Ser Ser (Email)

Tyr Glu Arg Lys Leu Gly Lys Val Ala Pro Thr Lys Glu Val Ser Ala Ala (SID #2)  
| | | | | | | | | | | | | | | | | | | |  
Tyr Glu Arg Lys Leu Gly Lys Val Ala Pro Thr Lys Glu Val Ser Ala Ala (Email)

Ile Trp Pro Phe Arg Phe Gly Tyr Asp Asn Glu Gly Trp Ser Ser (SID #2)  
Ile Trp Pro Phe Arg Phe Gly Tyr Asp Asn Glu Gly Trp Ser Ser (Email)

Thr Ile Leu Glu Ser Asp Ala Ser Lys Pro Tyr Met Gly Asn Asn Asp (SID #2)  
           |    |    |    |    |    |    |    |    |    |    |    |    |    |  
 Thr Ile Leu Glu Ser Asp Ala Ser Lys Pro Tyr Met Gly Asn Asn Asp (Email)

Pro Ser Thr Arg Tyr His Thr Trp Gly Ile Met Ala Leu Ser Arg Tyr (SID #2)  
| | | | | | | | | | | | | | | | | | | |  
Pro Ser Thr Arg Tyr His Thr Trp Gly Ile Met Ala Leu Ser Arg Tyr (Email)

Pro Ile Val Lys Ser Glu His His Leu Leu Pro Ser Pro Glu Gly Glu (SID #2)  
| | | | | | | | | | | | | | | | | |  
Pro Ile Val Lys Ser Glu His His Leu Leu Pro Ser Pro Glu Gly Glu (Email)

**Exhibit C****A Comparison of SEQ ID NO.:2 and the Nucleotide Sequence of the Email**

Ile Ala Pro Ala Ile Thr Leu Thr Val Asn Ile Ser Gly Lys Leu Val (SID #2)  
 | | | | | | | | | | | | | | | | | | | |  
 Ile Ala Pro Ala Ile Thr Leu Thr Val Asn Ile Ser Gly Lys Leu Val (Email)

Asp Phe Val Val Thr His Phe Gly Asn His Glu Asp Asp Leu Asp Arg (SID #2)  
 | | | | | | | | | | | | | | | | | | | |  
 Asp Phe Val Val Thr His Phe Gly Asn His Glu Asp Asp Leu Asp Arg (Email)

Lys Leu Gln Ala Ile Ala Val Ser Lys Leu Leu Lys Ser Ser Ser Asn (SID #2)  
 | | | | | | | | | | | | | | | | | | | |  
 Lys Leu Gln Ala Ile Ala Val Ser Lys Leu Leu Lys Ser Ser Ser Asn (Email)

Gln Val Ile Phe Leu Gly Tyr Ile Thr Ser Ala Pro Gly Ser Arg Asp (SID #2)  
 | | | | | | | | | | | | | | | | | | | |  
 Gln Val Ile Phe Leu Gly Tyr Ile Thr Ser Ala Pro Gly Ser Arg Asp

Tyr Leu Gln Leu Thr Glu His Gly Asn Val Lys Asp Ile Asp Ser Thr (SID #2)  
 | | | | | | | | | | | | | | | | | | | |  
 Tyr Leu Gln Leu Thr Glu His Gly Asn Val Lys Asp Ile Asp Ser Thr (Email)

Asp His Asp Arg Trp Cys Glu Tyr Ile Met Tyr Arg Gly Leu Ile Arg (SID #2)  
 | | | | | | | | | | | | | | | | | | | |  
 Asp His Asp Arg Trp Cys Glu Tyr Ile Met Tyr Arg Gly Leu Ile Arg (Email)

Leu Gly Tyr Ala Arg Ile Ser His Ala Glu Leu Ser Asp Ser Glu Ile (SID #2)  
 | | | | | | | | | | | | | | | | | | | |  
 Leu Gly Tyr Ala Arg Ile Ser His Ala Glu Leu Ser Asp Ser Glu Ile (Email)

Gln Met Ala Lys Phe Arg Ile Pro Asp Asp Pro Thr Asn Tyr Arg Asp (SID #2)  
 | | | | | | | | | | | | | | | | | | | |  
 Gln Met Ala Lys Phe Arg Ile Pro Asp Asp Pro Thr Asn Tyr Arg Asp (Email)

Asn Gln Lys Val Val Ile Asp His Arg Glu Val Ser Glu Lys Ile His (SID #2)  
 | | | | | | | | | | | | | | | | | | | |  
 Asn Gln Lys Val Val Ile Asp His Arg Glu Val Ser Glu Lys Ile His (SID #2)

Phe Asn Pro Arg Phe Gly Ser Tyr Lys Glu Gly His Asn Tyr Glu Asn (SID #2)  
 | | | | | | | | | | | | | | | | | | | |  
 Phe Asn Pro Arg Phe Gly Ser Tyr Lys Glu Gly His Asn Tyr Glu Asn (Email)

Asn His His Phe His Met Asn Thr Pro Lys Tyr Phe Leu (SID #2)  
 | | | | | | | | | | | | | | | | | | | |  
 Asn His His Phe His Met Asn Thr Pro Lys Tyr Phe Leu (Email)